Jody Vykoukal
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Background/Objectives:Cancer vaccine targets mostly include mutations and overexpressed proteins. However, cancer-associated post-translational modifications (PTMs) may also induce immune responses. Previously, our group established the enzyme protein arginine deiminase type-2 (PADI2), which catalyzes citrullination modification, is highly expressed in triple-negative breast cancer (TNBC), promoting antigenicity. Methods: Here, we show the workflow of designing citrullinated enolase 1 (citENO1) vaccine peptides identified from breast cancer cells by mass spectrometry and demonstrate TNBC vaccine efficacy in the mouse model. Immunized mice with citENO1 peptides or the corresponding unmodified peptides, plus Poly I:C as an adjuvant, were orthotopically implanted with a TNBC murine cell line. Results: Vaccination with citENO1, but not unmodified ENO1 (umENO1), induced a greater percentage of activated CD8+ PD-1+ T cells and effector memory T cells in skin-draining lymph nodes (SDLNs). Remarkably, the citENO1 vaccine delayed tumor growth and prolonged overall survival, which was further enhanced by PD-1 blockade. Conclusions: Our data suggest that cancer-restricted post-translational modifications provide a source of vaccines that induce an anti-cancer immune response.
Year:
2025
Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).
Year:
2025
Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR
Year:
2025
Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
Year:
2025
Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.
Year:
2025
Supplementary Table S2. Listing of protein features differentially expressed in Dox-inducible SPOPmut (F102C and F133V) C4-2b prostate cancer cells compared to C4-2b vector control shown in Fig. 2A upper panel
Year:
2025
Purpose: We conducted metabolomics and spatial cell transcriptomics of intraductal papillary mucinous neoplasms (IPMN), recognized pancreatic cancer precursors, to identify oncometabolites that inform upon risk of malignancy of IPMNs. Experimental Design: Untargeted metabolomic analyses were performed on cystic fluid from 125 patients with low-grade (LG) dysplasia or high-grade (HG) dysplasia with/without concurrent pancreatic ductal adenocarcinoma (PDAC; IPMN/PDAC). Predictive performance of individual metabolites for identifying HG or PDAC/IPMN was determined and compared with CA19-9 performance. Data were intersected with metabolic profiles of resected IPMN tissues and murine Kras;Gnas IPMN cell lines as well as spatial and single-cell transcriptomics of IPMNs. Results: A total of 388 metabolites were quantified in cystic fluid, of which 69 were differential ( P -value P -value P -value Conclusions: Cystic fluid polyamines offer utility for determining risk of malignancy of IPMNs that is complementary to CA19-9 and that has potential to aid in clinical management of patients with IPMNs.
Year:
2025
Supplemental Figure S7. Heatmap illustrating differences in gene-based signatures of immune cell types in epilesional (Epi), juxtalesional (Juxta), and perilesional (Peri) regions of high-grade (HG) and IPMN/PDAC compared to low-grade (LG) IPMN.
Year:
2025
Supplemental Figure S4. Scatter plots illustrating associations between cystic fluid spermidine, spermine, diacetylspermidine (DiAcSpmd), and acetylcadaverine (AcCad) [y-axis] and CA19-9 [x-axis].
Year:
2025
Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (17)
Jianjun Zhang
Professor
Indiana University Richard M Fairbanks School of Public Health
Hiroyuki Katayama
Research Group Leader
The University of Texas MD Anderson Cancer Center
Christian Maximillian Schmidt
Professor of Surgery
Indiana University School of Medicine
Timothy C. Thompson
Professor
The University of Texas MD Anderson Cancer Center
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Ehsan Irajizad
The University of Texas MD Anderson Cancer Center
Riccardo Ballarò
Senior Research Scientist
The University of Texas MD Anderson Cancer Center
Massimo Loda
Chair
Weill Cornell Medical College
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Eduardo Vilar
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rachelle Spencer
The University of Texas MD Anderson Cancer Center
yihui chen
The University of Texas MD Anderson Cancer Center
Michele Yip-Schneider
Senior Research Professor
Indiana University School of Medicine
Kim‐Anh Do
-
Anirban Maitra
Laura and Isaac Perlmutter Professor of Pathology
NYU Langone Health
Timothy Yap
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.